# Criterium

Source: https://onco.cc/companies/criterium/  
OnCo record `criterium` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Criterium is a US company in Saratoga Springs, New York, that is the lead sponsor of four cancer trials in OnCo, all testing other makers' drugs: fruquintinib with TAS-102 in colorectal cancer and tucatinib, alpelisib or palbociclib combinations in breast cancer.

## Summary

Criterium, Inc. is a company based in Saratoga Springs, United States (Wikidata Q140045287, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. It leads four trials recorded in OnCo, none of a compound of its own: NCT06992258 (phase 2, fruquintinib with TAS-102 against fruquintinib alone in refractory metastatic colorectal cancer), NCT05230810 (phase 1/2, alpelisib with tucatinib in PIK3CA-mutant HER2-positive metastatic breast cancer), NCT04567420 (DARE, phase 2, circulating tumour DNA-guided second-line adjuvant palbociclib and fulvestrant in high-risk ER-positive HER2-negative breast cancer) and NCT05458674 (phase 2, tucatinib with trastuzumab and eribulin in pretreated HER2-positive metastatic breast cancer). The cro-services type reflects that pattern; Criterium's own description of its business was not consulted.

## Fields

- Kind: Company
- Last checked: 2026-09-22
- Also known as: Criterium, Inc.; Criterium Inc
- Tags: ctgov-sponsor; wave5-sponsor
- HQ: Saratoga Springs, New York
- Type: cro-services
- Website: https://www.criteriuminc.com

## Sources

- Official website: https://www.criteriuminc.com
- Wikidata Q140045287: https://www.wikidata.org/wiki/Q140045287
- ClinicalTrials.gov: trials led by Criterium, Inc.: https://clinicaltrials.gov/search?lead=Criterium%2C%20Inc.

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- trials: [A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer](https://onco.cc/trials/nct06992258/), [Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.](https://onco.cc/trials/nct05230810/), [DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)](https://onco.cc/trials/nct04567420/), [Tucatinib+Trastuzumab+Eribulin in HER2+ MBC](https://onco.cc/trials/nct05458674/)

---
JSON: https://onco.cc/api/v1/entities/criterium.json